Cardiotoxicity of Anthracyclines.

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Anthracycline chemotherapy is a common cancer treatment.
• Cardiotoxicity is a significant side effect of anthracyclines, often leading to left ventricular systolic dysfunction within the first year of treatment.
• Clinical symptoms may not appear until significant damage has occurred.

Purpose of the Study:

• To highlight the importance of early detection of anthracycline-induced cardiotoxicity.
• To emphasize the necessity of comprehensive cardiovascular risk assessment before anthracycline therapy.
• To outline preventive strategies for mitigating cardiotoxicity.

Main Methods:

• Utilizing biomarkers for early detection of cardiac dysfunction.
• Employing cardiovascular imaging techniques for monitoring heart health.
• Conducting thorough cardiovascular risk assessments prior to treatment initiation.

Main Results:

• Early detection of cardiotoxicity is achievable through biomarkers and imaging, preceding clinical manifestation.
• Comprehensive risk assessment aids in stratifying patients based on their likelihood of developing cardiotoxicity.
• Preventive measures significantly reduce the incidence and severity of cardiotoxicity.

Conclusions:

• Proactive cardiovascular risk assessment and management are crucial for patients receiving anthracycline chemotherapy.
• Interventions such as dose modification, liposomal formulations, and cardioprotective agents like dexrazoxane can mitigate cardiotoxicity.
• Long-term follow-up and ongoing risk factor optimization are essential for cancer survivors to ensure optimal cardiovascular health.